phentodur phentermine (as hydrochloride) 15 mg modified release capsule blister pack
arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 18.666 mg - capsule, modified release - excipient ingredients: gelatin; sodium polystyrene sulfonate; iron oxide black; lactose monohydrate; brilliant blue fcf; titanium dioxide; magnesium stearate; iron oxide yellow; liquid paraffin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine sandoz phentermine (as hydrochloride) 40 mg sustained release capsule blister pack
aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 49.79 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; sunset yellow fcf; erythrosine; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine sandoz phentermine (as hydrochloride) 15 mg sustained release capsule blister pack
aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 18.67 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; quinoline yellow; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phentermine sandoz phentermine (as hydrochloride) 30 mg sustained release capsule blister pack
aspen pharmacare australia pty ltd - phentermine hydrochloride, quantity: 37.34 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; sodium polystyrene sulfonate; magnesium stearate; liquid paraffin; titanium dioxide; purified water; iron oxide red; gelatin; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - phentermine sandoz is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine sandoz can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
novaphen phentermine (as hydrochloride) 40 mg modified release capsule blister pack
nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 49.8 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: magnesium stearate; liquid paraffin; lactose; sodium polystyrene sulfonate; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate; carmoisine - novaphen is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with novaphen can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phenterin phentermine (as hydrochloride) 40 mg modified release capsule blister pack
nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 49.8 mg (equivalent: phentermine, qty 40 mg) - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; lactose; liquid paraffin; magnesium stearate; titanium dioxide; iron oxide yellow; sorbitan monolaurate; iron oxide red; gelatin; sodium lauryl sulfate; carmoisine - phenterin is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phenterin can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
novaphen phentermine (as hydrochloride) 30 mg modified release capsule blister pack
nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 37.3 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: lactose; sodium polystyrene sulfonate; liquid paraffin; magnesium stearate; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - novaphen is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with novaphen can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phenterin phentermine (as hydrochloride) 30 mg modified release capsule blister pack
nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 37.3 mg (equivalent: phentermine, qty 30 mg) - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; liquid paraffin; magnesium stearate; lactose; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate - phenterin is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phenterin can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
novaphen phentermine (as hydrochloride) 15 mg modified release capsule blister pack
nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 18.7 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: lactose; magnesium stearate; sodium polystyrene sulfonate; liquid paraffin; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - novaphen is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with novaphen can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
phenterin phentermine (as hydrochloride) 15 mg modified release capsule blister pack
nova pharmaceuticals australasia pty ltd - phentermine hydrochloride, quantity: 18.7 mg (equivalent: phentermine, qty 15 mg) - capsule, modified release - excipient ingredients: sodium polystyrene sulfonate; lactose; magnesium stearate; liquid paraffin; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate - phenterin is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phenterin can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.